Document Detail

Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis.
MedLine Citation:
PMID:  19918048     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine levels of interleukin 33 (IL-33) in serum and synovial fluid (SF) and their clinical associations in patients with rheumatoid arthritis (RA). To evaluate the ability of activated peripheral blood mononuclear cells (PBMC) and fibroblast-like synoviocytes (FLS) from RA patients to release IL-33. METHODS: Sera were obtained from 59 patients with RA, 10 patients with infectious diseases, and 42 healthy volunteers. SF samples were obtained from 15 patients with RA and 13 with osteoarthritis. IL-33 levels were measured using a sandwich ELISA after removal of rheumatoid factor with protein A-Sepharose beads. FLS were stimulated with IL-1beta and tumor necrosis factor, and treated with or without chemical damage. PBMC were stimulated with anti-CD3/CD28 antibodies. The levels of IL-33 were measured in the culture supernatants and cell lysates by ELISA or immunoblotting. RESULTS: Serum IL-33 levels were significantly higher in RA patients, especially in the high disease activity group compared to the moderate or low activity group. IL-33 levels in SF were elevated in all 15 RA patients measured. IL-33 levels were higher in SF samples than in sera in 7 RA patients measured simultaneously. The 30-kDa IL-33 precursor was detected in the culture supernatants of damaged FLS but was not detected in those of activated PBMC and non-damaged FLS. CONCLUSION: IL-33 levels were elevated in sera and SF samples from patients with RA, and correlated with disease activity. IL-33 was produced mainly in inflamed joints; IL-33/ST2L signaling might play an important role in joint inflammation of human RA.
Yasushi Matsuyama; Hitoaki Okazaki; Hiroyuki Tamemoto; Hirotaka Kimura; Yasuyuki Kamata; Katsuya Nagatani; Takao Nagashima; Morisada Hayakawa; Masahiro Iwamoto; Taku Yoshio; Shin-ichi Tominaga; Seiji Minota
Related Documents :
3440328 - Ultraviolet-a light in the treatment of rheumatoid arthritis.
21334048 - Single-center outcome of laparoscopic unilateral adrenalectomy for patients with primar...
12571838 - Eligibility of patients in routine care for major clinical trials of anti-tumor necrosi...
24269268 - Impact of harmonization of collection tubes on alzheimer's disease diagnosis.
12796128 - Relationship of activated partial thromboplastin time to coronary events and bleeding i...
1672858 - Neurohormonal factors in functional dyspepsia: insights on pathophysiological mechanisms.
Publication Detail:
Type:  Journal Article     Date:  2009-11-16
Journal Detail:
Title:  The Journal of rheumatology     Volume:  37     ISSN:  0315-162X     ISO Abbreviation:  J. Rheumatol.     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-30     Completed Date:  2010-04-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7501984     Medline TA:  J Rheumatol     Country:  Canada    
Other Details:
Languages:  eng     Pagination:  18-25     Citation Subset:  IM    
Division of Rheumatology and Clinical Immunology and Department of Biochemistry, Jichi Medical University, Tochigi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy,  metabolism*,  pathology,  physiopathology*
Cells, Cultured
Interleukins / metabolism*
Joints / immunology,  pathology
Leukocytes, Mononuclear / cytology,  immunology
Middle Aged
Signal Transduction / physiology
Synovial Fluid / immunology*
Reg. No./Substance:
0/Antirheumatic Agents; 0/IL33 protein, human; 0/Interleukins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Baseline Glucocorticoid Dose and Bone Mineral Density Response with Teriparatide or Alendronate Ther...
Next Document:  Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin orga...